Danone S.A (BN) Fair Value & Analysis
Consumer Defensive · FR · Market cap €39.0B
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Share price +18.2% over the past month.
Price vs Fair Value (12 months)
12‑month range €57.20 – €72.14 · fair‑value band €32.30 – €74.79 · the €67.62 price screens above the €50.26 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Danone S.A (BN) currently trades at €67.62, while our model-based Fair Value estimate is €50.26 — implying the stock looks roughly 25.7% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Danone S.A generated revenue of €27.3B at a net margin of 6.7%. Revenue declined 0.5% year over year. It earns a return on equity of 10.8%. Net debt stands at €13.1B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Danone S.A. operates in the food and beverage industry in Europe, Ukraine, North America, China, North Asia, the Oceania, Latin America, rest of Asia, Africa, Turkey, the Middle East, and the Commonwealth of Independent States. The company operates through Essential Dairy & Plant-Based, Specialized Nutrition, and Waters segments. It produces and distributes yogurts, dairy products, coffee creations and drinks, beverages, plant-based products, ice creams, frozen desserts, and cheese products. The company also provides specialized nutrition, including formulas and complementary feeding for babies and young children; and special medical purposes food for children and adults. In addition, it offers tube feeding products and oral nutritional supplements. Further, the company provides mineral waters from natural sources, waters infused with natural fruit extracts, fruit juices, and vitamins. The company offers its products under the Actimel, Activia, Alpro, Aptamil, Danette, Danio, Danoni…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Danone S.A reported revenue of €27.3B in FY2025 versus €24.3B in FY2021, a compound +3.0%/yr. Reported net income was €1.8B in FY2025, compounding −1.3%/yr from FY2021.
Open the full interactive analysis →
Recent news
- Exclusive Networks Appoints Sergio Amodeo as Group Chief Financial Officer
- Druid Sport Secures a Record Number of AFA Partnerships Across China
- Danone bets on protein with Made Group buy
- Danone strikes Asia-Pacific deal one-two
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NSRGF | $98.16 | $70.25 | -28% |
| Foshan Haitian Flavouring and Food Company 603288 | ¥33.04 | ¥25.65 | -22% |
| Nestlé India Limited NESTLEIND | ₹1,438 | ₹362.37 | -75% |
| Grupo Bimbo, S.A. BIMBOA | 57.10 MXN | 45.03 MXN | -21% |
| Uni-President Enterprises Corp 1216 | 75.10 TWD | 72.54 TWD | -3% |
| Britannia Industries Limited BRITANNIA | ₹5,218 | ₹3,567 | -32% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Danone S.A (BN) undervalued?
What is the fair value of BN?
What is the quality score of BN?
What is the revenue of Danone S.A (BN)?
What is the net profit margin of BN?
Does Danone S.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.